Responses
Oral Abstracts
Awards Ceremony & Plenary 4: Seminal Abstract Presentations
O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775
Compose a Response to This Article
Other responses
No responses have been published for this article.